Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC) has granted Novavax conditional marketing authorization (CMA) for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.
European Commission grants conditional marketing authorization for Novavax COVID-19 vaccine
December 20, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022